343 related articles for article (PubMed ID: 24579906)
21. Enterovirus 71 vaccine: close but still far.
Zhang D; Lu J; Lu J
Int J Infect Dis; 2010 Sep; 14(9):e739-43. PubMed ID: 20400350
[TBL] [Abstract][Full Text] [Related]
22. Development of an Enterovirus 71 Vaccine Efficacy Test Using Human Scavenger Receptor B2 Transgenic Mice.
Imura A; Sudaka Y; Takashino A; Tamura K; Kobayashi K; Nagata N; Nishimura H; Mizuta K; Koike S
J Virol; 2020 Feb; 94(6):. PubMed ID: 31896594
[TBL] [Abstract][Full Text] [Related]
23. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71.
Mao Q; Li N; Yu X; Yao X; Li F; Lu F; Zhuang H; Liang Z; Wang J
Arch Virol; 2012 Jan; 157(1):37-41. PubMed ID: 21984267
[TBL] [Abstract][Full Text] [Related]
24. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71.
Zhang C; Yang Y; Chi Y; Yin J; Yan L; Ku Z; Liu Q; Huang Z; Zhou D
Vaccine; 2015 Sep; 33(39):5087-94. PubMed ID: 26296491
[TBL] [Abstract][Full Text] [Related]
25. Inactivated enterovirus 71 with poly-γ-glutamic acid/Chitosan nano particles (PC NPs) induces high cellular and humoral immune responses in BALB/c mice.
Pathinayake PS; Gayan Chathuranga WA; Lee HC; Chowdhury MYE; Sung MH; Lee JS; Kim CJ
Arch Virol; 2018 Aug; 163(8):2073-2083. PubMed ID: 29619599
[TBL] [Abstract][Full Text] [Related]
26. Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children.
Li JX; Song YF; Wang L; Zhang XF; Hu YS; Hu YM; Xia JL; Li J; Zhu FC
Expert Rev Vaccines; 2016; 15(1):129-37. PubMed ID: 26460695
[TBL] [Abstract][Full Text] [Related]
27. A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge.
Lin YL; Chow YH; Huang LM; Hsieh SM; Cheng PY; Hu KC; Chiang BL
Sci Rep; 2018 Jul; 8(1):10713. PubMed ID: 30013088
[TBL] [Abstract][Full Text] [Related]
28. Diseases caused by enterovirus 71 infection.
Lee TC; Guo HR; Su HJ; Yang YC; Chang HL; Chen KT
Pediatr Infect Dis J; 2009 Oct; 28(10):904-10. PubMed ID: 20118685
[TBL] [Abstract][Full Text] [Related]
29. Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines.
Liang Z; Mao Q; Gao Q; Li X; Dong C; Yu X; Yao X; Li F; Yin W; Li Q; Shen X; Wang J
Vaccine; 2011 Dec; 29(52):9668-74. PubMed ID: 22015395
[TBL] [Abstract][Full Text] [Related]
30. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses.
Cai Y; Ku Z; Liu Q; Leng Q; Huang Z
Vaccine; 2014 May; 32(21):2406-12. PubMed ID: 24657161
[TBL] [Abstract][Full Text] [Related]
31. Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides.
Li X; Mao C; Ma S; Wang X; Sun Z; Yi Y; Guo M; Shen X; Sun L; Bi S
Biochem Biophys Res Commun; 2009 Dec; 390(4):1126-8. PubMed ID: 19799860
[TBL] [Abstract][Full Text] [Related]
32. Viral and host factors that contribute to pathogenicity of enterovirus 71.
Huang HI; Weng KF; Shih SR
Future Microbiol; 2012 Apr; 7(4):467-79. PubMed ID: 22439724
[TBL] [Abstract][Full Text] [Related]
33. Molecular epidemiology and evolution of human enterovirus 71 and hand, foot and mouth disease.
Liu ZF; Gui JJ; Hua QH; Dong CZ
Yi Chuan; 2015 May; 37(5):426-35. PubMed ID: 25998430
[TBL] [Abstract][Full Text] [Related]
34. Recent Progress towards Novel EV71 Anti-Therapeutics and Vaccines.
Ng Q; He F; Kwang J
Viruses; 2015 Dec; 7(12):6441-57. PubMed ID: 26670245
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the enterovirus 71 P1 polyprotein expressed in Pichia pastor as a candidate vaccine.
Han X; Ying XL; Zhou SL; Han T; Huang H; Jin Q; Yang F; Sun QY; Sun XX
Hum Vaccin Immunother; 2014; 10(8):2220-6. PubMed ID: 25424925
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of a national enterovirus 71 vaccination program in China.
Wang W; Song J; Wang J; Li Y; Deng H; Li M; Gao N; Zhai S; Dang S; Zhang X; Jia X
PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005899. PubMed ID: 28892475
[TBL] [Abstract][Full Text] [Related]
37. Is a multivalent hand, foot, and mouth disease vaccine feasible?
Klein M; Chong P
Hum Vaccin Immunother; 2015; 11(11):2688-704. PubMed ID: 26009802
[TBL] [Abstract][Full Text] [Related]
38. Enterovirus 71 vaccine acceptance among parents of children < 5 years old and their knowledge of hand, foot and mouth disease, Chongqing, China, 2017.
Qi L; Su K; Xia Y; Tang W; Shen T; Li Q
PLoS One; 2019; 14(11):e0225569. PubMed ID: 31774839
[TBL] [Abstract][Full Text] [Related]
39. Towards broadly protective polyvalent vaccines against hand, foot and mouth disease.
Liu Q; Tong X; Huang Z
Microbes Infect; 2015 Feb; 17(2):155-62. PubMed ID: 25449959
[TBL] [Abstract][Full Text] [Related]
40. [Research into the Pathogenicity of Enterovirus 71].
Sun L; Wen H; Wang Z
Bing Du Xue Bao; 2015 Mar; 31(2):192-6. PubMed ID: 26164947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
